The Coalition for Epidemic Preparedness Innovation (CEPI) has partnered with the Brighton Collaboration to support the safety assessment of its candidate vaccines, including SARS-COV-2. Four AESI have been targeted for case…
Several protein vaccine candidates are among the COVID-19 vaccines in development. The Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) as part of the Safety Platform for Emergency Vaccines (SPEAC) project has…
The Coalition for Epidemic Preparedness Innovations (CEPI) has contracted with the Brighton Collaboration, through the Task Force for Global Health (TFGH), to harmonize the safety assessment of CEPI-funded vaccines via…
Since the emergence of a new coronavirus, SARS-CoV-2, in China, there has been an unprecedented need to quickly develop an effective vaccine in light of the pandemic that was declared…
This is a Brighton Collaboration case definition of the term "Sensorineural Hearing Loss" (SNHL) to be utilized in the evaluation of adverse events following immunization. The case definition was developed…
The COVID-19 pandemic has devastated the world as we know it. Nucleic acid (DNA and RNA) vaccines are among the most advanced vaccines for COVID-19 under development. These vaccine technology…
The Coalition of Epidemic Preparedness Innovations (CEPI) has partnered with the Brighton Collaboration (BC), a program of the Task Force for Global Health, to support the harmonized safety assessment of its vaccine candidates.As part…
Our previous post entitled Transition of Brighton Collaboration informed you of several new developments to strengthen the Brighton Collaboration, including our move to the Task Force for Global Health (TFGH;…
Dear Partners and Visitors As announced on the 21st of May 2019, the Brighton Collaboration will be dissolved as a Partnership under Swiss law and reconstituted as a programme of the Task Force…